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Abstract
The aim of our study was to determine the epidemiological profile and the antibiotic susceptibility of bacteria and fungi identified from blood
cultures in the patients of the clinical haematology unit. A retrospective study was carried out over an 8-year period (2003–2010) in the
clinical haematology unit of the Percy Military Medical Center. During this period, we collected 723 isolates: Gram-negative bacilli (70.8%)
and Gram-positive cocci (18.7%). The four most commonly isolated species were Escherichia coli (18.5%), Pseudomonas aeruginosa (14.8%),
Stenotrophomonas maltophilia (6.2%) and Staphylococcus epidermidis (5.4%). The rate of methicillin-resistant Sthaphylococcus aureus was 6.45%
and that of coagulase-negative staphylococci 61.2%. No resistance to glycopeptides was observed. In E. coli, as in the Klebsiella-Ente-
robacter-Serratia group, a 27% resistance to fluoroquinolones was observed. Concerning P. aeruginosa, the phenotypes were distributed
over penicillinase (23.4%) and cephalosporinase (13.1% were resistant to ceftazidime). The impermeability rate of imipenem was 9.3%. The
aggressiveness and duration of haematological treatments explains why infections remain one of the main complications of neutropenia.
The emergence of new or unusual bacteria is highly likely. Antibiotic selective pressure and long periods of hospitalization could explain the
emergence of multiresistant bacteria. As a consequence, epidemiological surveillance is indispensable.
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Introduction
Infections are serious and frequent complications of cytotoxic
chemotherapy-induced neutropenia. Seventy per cent of
patients with agranulocytosis or who receive haematopoietic
stem cells transplantation develop a fever [1]. The mortality
rate is high: 5% in the case of bacteraemias associated with
Gram-positive cocci (GPC) and 18% in the case of those
associated with Gram-negative bacilli (GNB) [2]. For 30 years,
the epidemiology of bacterial infections in these patients has
evolved. In the seventies, and until the mid-eighties, the
reports from the febrile neutropenic antibiotherapy study
group of the EORTC (European Organisation for Research
and Treatment of Cancer) showed that in 60% to 70% of cases,
bacteraemia in this population was related to GNB [3]. By the
end of the 1980s, the proportions reversed to a greater
percentage of GPC, before tending towards a balanced
situation following the year 2000. The study previously
performed in the onco-haematology department of our
hospital revealed the variability of these data [4]. Almost
10 years later, it appeared necessary to review the blood
culture flora sampled in onco-haematology and to compare
the results with the literature. Our aim was to improve the
understanding of the impact of various therapeutic scenarios
on the flora, and to optimize probabilistic antibiotherapy
during episodes of febrile neutropenia.
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Methods
We performed a retrospective study, between 1 January 2003
and 31 December 2010, in the Clinical Haematology Depart-
ment of the Military Medical Centre Percy. This is a 23-bed
department, with 10 rooms devoted to intensive care. It
handles acute and chronic haematological malignancies and
also undertakes procedures related to chemotherapy, auto-
grafting and allografting. All of the studied blood culture
isolates were validated by the physician and communicated to
the clinician. Ten millilitres of venous blood were inoculated
into aerobic and anaerobic bottles using the BacT/Alert 3D
system (BioMerieux, Marcy l’Etoile, France). The bottles
were incubated at 37°C with constant stirring for 6 days,
before being considered as sterile. All positive cultures were
subcultured on enriched media: blood agar, boiled blood agar,
Sabouraud agar and Schaedler agar (BioMerieux), under
anaerobic conditions whenever necessary. An initial examina-
tion was carried out followed by another examination after
Gram staining. Based on examination, a biochemical identifi-
cation using the API system (BioMerieux) was inoculated
directly from the blood culture broth. An antibiogram was also
carried out, following the guidelines of the Antibiogramme
Committee of the French Society for Microbiology (CA-SFM).
An antifungigram was systematically carried out using the
E-test technique (BioMerieux), whenever the isolate con-
tained a fungus. The inhibition zone or E-test diameters were
read by a SIRSCAN analyzer (i2a, Perols, France).
The data were gathered using the ‘epidemiological’ module
of the SIR software (i2a), with individualized analyses of the
species and their resistance profiles. The bacteria belonging to
commensal flora (coagulase-negative staphylococcus and Co-
rynebacteria sp.) were retained if they were isolated at least
twice with the same antibiotype. Duplicates (even isolates with
the same sensitivity profile, isolated several times in the same
patient over a period of at least 5 days) were excluded.
Patients
The colistin–amphotericin B combination is used in our
hospital for selective digestive decontamination (SDD). During
allogeneic bone marrow transplantation (BMT), patients
receive primary antibioprophylaxis based on a combination
of ciprofloxacin and a piperacillin/tazobactam. In the case of
febrile neutropenia, the most urgent issue is antibacterial
therapy, based on an empirical broad-spectrum antibiotherapy.
The protocol applied in our haematology department relies on
a dual empirical antibiotherapy according to the Infectious
Diseases Society of America (piperacillin/tazobactam and
amikacin) for 3 days [5]. The combination with aminoglycoside
is not recommended by the European Conference on Infection
in Leukemia unless septic shock or pneumonia occurs [6]. In
the case of persistent fever, antibacterial therapy relies on
ceftazidime and vancomycin and amikacin. This first-line
treatment regimen is maintained if effective and/or if the
isolated bacterial species is sensitive to this combination. If a
resistant GNB is isolated, the spectrum is enlarged to include
third-generation cephalosporins (3GC) or even imipenem in
the case of ESBL (extended-spectrum betalactamase-producing
enterobacteria), which hydrolyze 3GC. If a GPC is isolated,
vancomycin is given. This antibiotic can be added at an early
stage in the case of an MRSA-carrier patient. Finally, the
addition of an antifungal drug (amphotericin B) can become
necessary if a fungal infection is isolated or suspected.
Results
Patient profiles, frequency and distribution of species
Over an 8-year period, 1413 patients were hospitalized in our
haematology department. Of these, 829 had neutropenia with
<1000 neutrophils/mm3 (grade 3 according to the WHO
classification [7]). Among these 1413 patients, 737 had at least
one grade 4 neutropenic episode (<500 neutrophils/mm3).
During this period, 6412 blood culture samples (an anaerobic
bottle followed by an aerobic bottle) were performed and 723
positive blood culture isolates were identified (i.e. 11.3% of the
blood culture samples were positive). During this period, 89
patients underwent an allogeneic BMT. The frequency and
distribution of species are presented in Table 1. The most
important result of this study is the variation of the epidemi-
ology of bacteraemia: the GPC represent 18.7% (n = 135) of
the isolates, and the GNB represent 70.8% (n = 512). The
dynamics of the results (Fig. 1) provide a perfect illustration of
the variability of these data. The four most commonly isolated
species were Escherichia coli (18.5%, n = 134), Pseudomonas
aeruginosa (14.8%, n = 107), Stenotrophomonas maltophilia
(6.2%, n = 45) and Staphylococcus epidermidis (5.4%, n = 39).
The GPC isolates consisted mainly of S. epidermidis (28.9%),
Sthaphylococcus aureus (23%, n = 31) and Enterococcus sp.
(17.8%, n = 24), of which 55% were E. faecalis (n = 13). The
enterobacteriaceae isolates consisted mainly of E. coli (51.7%)
and bacteria from the Klebsiella-Enterobacter-Serratia (KES)
group (40.9%, n = 106). The non-fermenting GNB (NF-GNB)
were dominated by P. aeruginosa (42.3%, of which 35% were of
serotype 6), S. maltophilia (17.8%) and Acinetobacter sp. (16.6%,
n = 42), of which 64.3% were Acinetobacter baumannii (n = 27).
The NF-GNB represented 49.4% of the GNB (n = 253/512
GNB). Among the other NF-GNB, mainly Pseudomonas
non-aeruginosa (7.5%, n = 19), in particular Pseudomonas fluo-
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rescens and Pseudomonas putida, were found. These were
followed by Sphingomonas sp. (4.3%, n = 11).
Resistance distribution
Antibiotic susceptibilities were studied by class of antibiotic.
Only two of the S. aureus isolated from blood cultures
between 2003 and 2010 were methicillin resistant
(MRSA = 6.5%). However, 61.2% (n = 30) of coagulase-nega-
tive staphylococci harboured this resistance. Considering
glycopeptides, one S. epidemidis strain showed an intermediate
resistance to teicoplanin, but was sensitive to vancomycin. No
strain of S. aureus was isolated with an intermediate resistance
to glycopeptide antibiotics. Sixty per cent (n = 81) of acquired
penicillinase and 27% (n = 36) of high-level penicillinase were
observed in E. coli. Almost 4% (n = 10) of the enterobacteri-
aceae were resistant to 3GC, the phenotypes were hyper-
production of the chromosomal cephalosporinase in five
Enterobacter sp. and ESBL in five E. coli. In E. coli, as in the
KES group, 27% were resistant to fluoroquinolones (this rate
was 10% in the previous study from 1996 to 2002). Concern-
ing the NF-GNB, especially for P. aeruginosa, the phenotypes
were distributed over penicillinase (23.4%, n = 25) and
cephalosporinase (13.1% were resistant to ceftazidime,
n = 14). The impermeability rate of imipenem was 9.3%
(n = 10). In the case of Acinetobacter sp., the resistance rates
were similar: 16.7% (n = 7) were resistant to ticarcillin. None
of the isolated Acinetobacter sp. were resistant to imipenem
and to the piperacillin-tazobactam combination, and 31%
(n = 13) were resistant to fluoroquinolones. For the 45
isolated strains of S. maltophilia, the in vitro resistance rates
were as follows (R%): ticarcillin-clavulanic acid (31%, n = 14),
piperacillin-tazabactam (62%, n = 28), ciproflaxin (27%,
n = 12), trimethoprim-sulphamethoxazole (4%, n = 2). For-
ty-nine per cent (n = 22) of the strains were resistant to
amikacin and 49% (n = 22) were resistant to ceftazidime.
Discussion
Patients
Patients with onco-haematological diseases combine multiple
infection risk factors: immunodeficiency, modification of the
TABLE 1. Distribution by species
2003 2004 2005 2006 2007 2008 2009 2010 Total % Family
Streptococcus mitis 1 2 3 2 0 3 1 0 12 1.7 Streptococcaceae
Oral streptococcus 1 1 1 1 1 3 0 4 12 1.7
Streptococcus pneumoniae 0 0 1 0 0 0 0 0 1 0.1
Enterococcus sp. 3 2 7 3 0 5 2 2 24 3.3
Streptococcus (A-G) 1 0 2 0 2 0 0 1 6 0.8
Staphylococcus epidermidis 3 7 5 5 6 7 3 3 39 5.4 Staphylococcaceae
Staphylococcus hominis 0 0 0 0 0 0 0 0 0 0.0
Staphylococcus haemolyticus 0 0 0 0 0 0 1 0 1 0.1
Other coagulase-negative Staphylococcus 0 0 4 0 1 1 1 2 9 1.2
Staphylococcus aureus 3 6 4 2 6 4 2 4 31 4.3
All GPC 12 18 27 13 16 23 10 16 135 18.7 GPC
Escherichia coli 12 15 22 16 10 24 17 18 134 18.5 Enterobacteriaceae
KES 5 4 10 9 18 19 23 18 106 14.7
Salmonella sp. 1 0 0 0 0 0 0 0 1 0.1
Other 3 2 1 2 0 2 5 3 18 2.5
Total enterobacteriaceae 21 21 33 27 28 45 45 39 259 35.8
Pseudomonas aeruginosa 18 13 13 13 9 8 17 16 107 14.8 Non-fermenting
Acinetobacter sp. 4 1 4 6 7 5 8 7 42 5.8
Stenotrophomonas maltophilia 0 0 6 10 6 7 8 8 45 6.2
Other NF-GNB 2 4 6 8 7 7 16 9 59 8.2
All NF-GNB 24 18 29 37 29 27 49 40 253 35.0
All GNB 45 39 62 64 57 72 94 79 512 70.8 GNB
Anaerobics 1 1 0 1 0 0 0 1 4 0.6
Other species 9 7 4 11 9 8 5 6 59 8.2
Yeast 0 1 0 4 1 1 4 2 13 1.8
FIG. 1. Illustration of the variations in isolated species over a period of 15 years (ordonate, positive bloodstream (%); GPC, Gram-positive cocci;
NF-GNB, non-fermenting Gram negative bacilli (Pseudomonas aeruginosa, Acinetobacter, Stenotrophomonas maltophilia…)); GNB, Gram-negative bacilli).
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endogenous flora, and alteration of the skin and intestinal
barriers by catheters and chemotherapy. As the latter
phenomenon can lead to life threatening bacteremia, SDD
can be carried out in patients with grade 4 neutropenia. This
SDD is prescribed during aplasias following allogeneic and
autologous BMT and induction chemotherapy for acute
leukaemias, in order to reduce the digestive bacterial concen-
tration of GNB species [8]. The investigation of cases of fever
in neutropenic patients will include carrying out a stool
culture, an ECBU, a chest X-ray and blood cultures taken at
the same time (if needed) from central and peripheral
catheters, to elucidate the involvement of the central catheter
in the sepsis [9]. Nevertheless, from the microbiological point
of view, nearly 70% of febrile neutropenia cases remain
undocumented [10,11]. The increasing use of highly active
cytotoxic treatments and allografts has led to an increase in
the number of neutropenic patients treated in onco-haema-
tology. Over a period of 8 years, the neutropenic population
represented almost 60% of patients hospitalized in our
department. These patients are at risk of infection: during
the period 2003–2010, 46% of patients had one or more
bacteraemias during a grade 3 neutropenic episode.
Microbiology
The main feature of these trends is the constant increase in
GNB, in particular NF-GNB, in absolute numbers and incidence
rate. Table 2 shows the variation in absolute terms of the
various bacterial families or species between 1996–2002 and
2003–2010. With essentially equal numbers of blood cultures
included in the two study periods, 2 times as many E. coli, 2.5
times as many NF-GNB and 3 times more KES, were isolated in
the second period than in the first. The NF-GNB have followed
the evolution of GNB; 15 years ago they already represented
half of all isolated GNB. The first isolated species in our study is
E. coli. This result is in line with various studies dealing with
large series of immunocompetent and immunosuppressed
patients [12–15]. Other studies performed in patients with
well-established cancer showed the opposite trend (i.e. a
predominance of GPC, in particular negative coagulase staph-
ylococcus). However, very few studies of the microbiology of
bacteraemia in onco-haematology patients have been pub-
lished. A study performed in India has shown that in
hospitalized patients with acute myeloid leukaemia and pre-
senting with bacteraemia, the most commonly encountered
species was P. aeruginosa, followed by enterobacteriaceae such
as Klebsiella pneumoniae and E. coli [16]. In 2008, Cattaneo et al.
[17] revealed a change in the epidemiology of bacteraemia in
patients with haematological malignancies and an increase of
E. coli, but also of P. aeruginosa. Finally, in a recent study of
haematology patients by the same authors between June 2004
and January 2010, from 441 positive blood cultures nearly 60%
were identified as GNB, of which 66 were P. aeruginosa (15%)
[18]. Another study, carried out over a 1-year period, showed
that in neutropenic patients coagulase-negative staphylococci
represented more than 50% of blood culture isolates [3].
Similar results were reported in 2009 by a Moroccan team [19].
This re-emergence of GNB can be partially explained by a
decrease in the prophylactic use of fluoroquinolones and the
treatment of cases of febrile neutropenia [20]. It can also be
explained by the lack of active antibacterial agents for naturally
multi-resistant species (Acinetobacter, P. aeruginosa and
S. maltophilia). In our department, fluoroquinolones are only
used as a prophylaxis for allogeneic BMT, and on a case-by-case
basis, when the patient’s renal function contraindicates the use
of aminoglycosides and for the induction of acute leukaemia.
The influence of SDD is more difficult to evaluate:
theoretically, it targets the Gram-negative digestive reservoir,
in particular emerging P. aeruginosa. Although they are natu-
rally resistant to colistin, Proteus, Serratia and Providencia do not
emerge. SSD thus remains controversial as a daily practice, and
if using SDD might reduce bacteraemia rates, infection-related
fatality rates are not reduced [21]. Selective pressure related
to empirical first-line treatment of febrile neutropenia could
also partially explain the growing incidence of P. aeruginosa.
Among the various GNBs, S. maltophilia occupies a central
position. This trend was also observed by another team [22].
This increase in incidence rate raises difficulties, especially in
terms of treatment, as a consequence of the natural resistance
of this species, in particular to carbapenems. The respiratory
and gastrointestinal tracts are reservoirs for S. maltophilia. The
TABLE 2. Epidemiology between 1996–2002 and 2003–2010
Positive blood culture GPC GNB
Enterobacteriacae
NF GNB Anaerobic Yeast Other speciesaEscherichia coli KES Other
Study 1996–2002 690 432 (62.6%) 216 (31.3%) 60 38 14 104 9 10 23
Study 2003–2010 723 135 (18.7%) 512 (70.8%) 134 106 19 253 4 13 59
p 0.001 p 0.001
aHaemophilus sp., Campylobacter sp., Branhamella sp., Bacillus sp.
Statistical analysis was performed using the chi-square test; GPC, Gram-positive cocci; NF-GNB, non-fermenting Gram-negative bacilli (Pseudomonas aeruginosa, Acinetobacter,
Stenotrophomonas maltophilia…); GNB, Gram-negative bacilli.
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increase in S. maltophilia bacteraemia, which reveals antibiotic
selective pressure, needs to be carefully monitored as a
consequence of the risk of a therapeutic impasse. For the
forty-five patients with S. maltophilia bacteraemia, it would be
interesting to know the number of treatments including
imipenem prior to the bacteraemia; unfortunately these data
are difficult to record in a retrospective study.
In parallel with this phenomenon, the incidence of GPC has
decreased. This decline has multifactorial origins: a decrease
through improved control of the implementation and moni-
toring of central venous lines, the controlled prescription of
fluoroquinolones [23] and the appropriate use of glycopep-
tides. The rate at which anaerobic bacteria are isolated remains
low, and similar to the rates found in the literature [24]. The
proportion of candidaemia also remains low, with no change
with respect to the last decade. The 2012 data from the
‘Interscience Conference on Antimicrobial Agents and Che-
motherapy’ reveals a 2% incidence in grafted patients [25]. In
the present study, only three cases of candidaemia (i.e. an
incidence rate of 0.4%), all of which occurred in grafted
patients, were observed. The study of patients’ stool flora in
onco-haematology, allowing on one hand the SDD to be
confirmed, and on the other hand a probabilistic antibiotherapy
to be adapted in the case of febrile episodes, reveals
discrepancies in the data [26]. Indeed, in the same 2003–2010
study period, quantitative stool cultures revealed a clear
predominance of GPC, enterococci in particular. GNBs were
rarely isolated from quantitative stool cultures. Nevertheless,
the study of this stool flora does not allow digestive translo-
cations to be predicted or an antibiotherapy to be adapted.
These data partially explain why the systematic monitoring of
digestive flora in neutropenic patients remains controversial
[27] and is no longer performed in many hospitals.
Resistance
The main purpose of a surveillance of a specific disease such as
bacteraemia is to detect shifts in antimicrobial susceptibility of
the involved bacteria and should guide the choice of an
empirical therapy. The rate of penicillinase was 60%, as
opposed to 51% to 60% reported in various studies [26].
Furthermore, the 1998–2009 ONERBA study of the monitor-
ing of bacteraemia reveals a 12% fall in the sensitivity of
enterobacteria to fluoroquinolones, with a sensitivity of 80%
to 85%. In our department, the rate of ciprofloxacin resistance
is higher (25%), despite the absence of fluoroquinolones in the
treatment protocols. This significant increase of ciprofloxacin
resistance was described by European Centre for Disease
Prevention and Control (ECDC) in invasive French E. coli
between 2001 (9%) and 2010 (between 10% and 25%) [28]. In
the literature, 5% of bacteraemia are related to ESBL [29]. In
our work, a slight (4%) but not significant increase of ESBL was
identified. In NF-GNB, the study of P. aeruginosa resistance to
‘anti-pseudomonas’ molecules reported similar or even lower
resistance rates than those reported by the ONERBA and
ECDC: 60% to 65% sensitivity to ticarcillin vs. 75% in our
study, and 75% to 85% of strains sensitive to ceftazidime vs.
87%. The resistance of P. aeruginosa to imipenem is mainly
related to the loss of D2 porin: the resistance rates found by
ONERBA and in our study are close to 10% [26], whereas
ECDC found a resistance rate of 17.8% [28]. Fluoroquinolones
and aminoglycosides remain highly efficient and these must be
used in combination. According to the studies, the resistances
to ciprofloxacin and amikacin vary respectively from 60% to
80% and from 80% to 90% [28–31]. Furthermore, no
carbapenemase or methylase producing bacteria were isolated.
In our work, a small proportion (6.5%) of oxacillin-resistant
S. aureus was identified. This feature is discordant with ECDC,
which reported a rate of oxacillin resistance among S. aureus
of 21.6% [28]. This feature may be explained in part by the low
number of strains in our work. No vancomycin-resistant
Enterococcus sp. was detected, despite the use of this
glycopeptide as a second-line treatment for febrile neutrope-
nia. Table 3 shows the change in resistance of the main
bacterial species, between 1996–2002 and 2003–2010.
Conclusion
The aggressiveness and duration of antineoplastic therapy
explains why infections remain one of the main complications
TABLE 3. Antibiotic resistance between 1996–2002 and 2003–2010
MRSA
Coagulase negative
Staphylo-coccus
methicillin-resistant
Escherichia coli -
Penicilli-nase
E coli -
ESBL
E coli –
fluoroquinolones
resistance
Pseudomonas aeruginosa
– resistance ticarcillin,
ceftazidime, imipenem Stenotrophomonas
maltophilia – Ticarcillin-
clavulanic acid resistanceTic Caz Imi (D2)
Study 1996–2002 11.8% 65% 60% 0% 10% 25.5% 8.5% 6.4% 21.4%
Study 2003–2010 6.45% 61.2% 60% 4% 25% 23.4% 13.1% 9.3% 31%
NS p 0.001 NS
Statistical analysis was performed using the chi-square test; NS, not significant; MRSA, methicillin resistant Sthaphylococcus aureus; ESBL, extended spectrum beta lactamase; Tic,
ticarcillin; Caz, ceftazidime; Imi, imipenem.
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of neutropenia. In this context, the emergence of new or
unusual bacteria is highly likely. Antibiotic selective pressure
and long periods of hospitalization could explain the emer-
gence of multiresistant bacteria. As a consequence, epidemi-
ological surveillance is indispensable. The evolution of flora
towards GNB should encourage the highest level of caution.
Moreover, the results of this study lead us to question the
correct observance of SDD in neutropenic patients. A
prospective study of bacteraemia in neutropenic patients
would allow this crucial debate to be taken further.
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